BridgeBio Pharma (BBIO) Other Accumulated Expenses (2018 - 2026)

BridgeBio Pharma has disclosed Other Accumulated Expenses across 9 years of filings, most recently posting $135.5 million for Q1 2026.

• Other Accumulated Expenses for Q1 2026 came in at $135.5 million, up 233.16% year-over-year; the trailing twelve-month figure through Mar 2026 was $135.5 million (up 233.16% YoY), and the FY2025 annual result was $120.2 million, up 263.53% from the prior year.
• Other Accumulated Expenses came in at $135.5 million for Q1 2026 at BridgeBio Pharma, up from $120.2 million in the prior quarter.
• In the past five years, Other Accumulated Expenses ranged from a high of $135.5 million in Q1 2026 to a low of $4.7 million in Q4 2023.
• The 5-year median for Other Accumulated Expenses is $23.0 million (2022), against an average of $36.2 million.
• Across the five-year window, Other Accumulated Expenses plunged 82.86% in 2022 and jumped 615.83% in 2025, its largest moves.
• BridgeBio Pharma's Other Accumulated Expenses stood at $5.2 million in 2022, then dropped by 10.27% to $4.7 million in 2023, then jumped by 610.14% to $33.1 million in 2024, then jumped by 263.53% to $120.2 million in 2025, then grew by 12.72% to $135.5 million in 2026.
• The last three Other Accumulated Expenses figures came in at $135.5 million (Q1 2026), $120.2 million (Q4 2025), and $92.7 million (Q3 2025), per Business Quant data.